AbbVie Inc. (ABBV) financial statements: income statement, balance sheet and cash flow

AbbVie Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), AbbVie Inc. reported revenue of $61.2B (+8.6% year on year) and net income of $4.2B (-1.2% year on year).

Income statement

AbbVie Inc. income statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Net revenues	$61.2B	$56.3B	$54.3B	$58.1B
Cost of products sold	$18.2B	$16.9B	$20.4B	$17.4B
Selling, general and administrative	$14.0B	$14.8B	$12.9B	$15.3B
Research and development	$9.1B	$12.8B	$7.7B	$6.5B
Acquired IPR&D and milestones	$5.0B	$2.8B	$778.0M	$697.0M
Other operating income	($241.0M)	($7.0M)	($179.0M)	$56.0M
Total operating costs and expenses	$46.1B	$47.2B	$41.6B	$39.9B
Operating earnings	$15.1B	$9.1B	$12.8B	$18.1B
Interest expense, net	$2.6B	$2.2B	$1.7B	$2.0B
Net foreign exchange loss	$58.0M	$21.0M	$146.0M	$148.0M
Other expense, net	$5.8B	$3.2B	$4.7B	$2.4B
Earnings before income tax expense	$6.6B	$3.7B	$6.3B	$13.5B
Income tax expense (benefit)	$2.4B	($570.0M)	$1.4B	$1.6B
Net earnings	$4.2B	$4.3B	$4.9B	$11.8B
Net earnings attributable to noncontrolling interest	$7.0M	$8.0M	$10.0M	$9.0M
Net earnings attributable to AbbVie Inc.	$4.2B	$4.3B	$4.9B	$11.8B
Basic earnings per share (in dollars per share)	$2.37	$2.40	$2.73	$6.65
Diluted earnings per share (in dollars per share)	$2.36	$2.39	$2.72	$6.63
Weighted-average basic shares outstanding (in shares)	1.8B	1.8B	1.8B	1.8B
Weighted-average diluted shares outstanding (in shares)	1.8B	1.8B	1.8B	1.8B

AbbVie Inc. income statement, quarters

Line item	Jun 30, 2026 · Q2	Mar 31, 2026 · Q1	Sep 30, 2025 · Q3	Jun 30, 2025 · Q2
Net revenues	$17.0B	$15.0B	$15.8B	$15.4B
Cost of products sold	$4.3B	$4.2B	$5.3B	$4.3B
Selling, general and administrative	$3.6B	$3.6B	$3.6B	$3.3B
Research and development	$2.3B	$2.5B	$2.3B	$2.1B
Acquired IPR&D and milestones	$291.0M	$744.0M	$2.7B	$823.0M
Other operating income	$0	—	$0	$24.0M
Total operating costs and expenses	$10.6B	$11.0B	$13.9B	$10.5B
Operating earnings	$6.4B	$4.0B	$1.9B	$4.9B
Interest expense, net	$679.0M	$645.0M	$667.0M	$678.0M
Other expense, net	$1.5B	$2.3B	$503.0M	$2.6B
Earnings before income tax expense	$4.3B	$1.0B	$714.0M	$1.6B
Income tax expense	$662.0M	$342.0M	$526.0M	$613.0M
Net earnings	$3.6B	$697.0M	$188.0M	$941.0M
Net earnings attributable to noncontrolling interest	$3.0M	$2.0M	$2.0M	$3.0M
Net earnings attributable to AbbVie Inc.	$3.6B	$695.0M	$186.0M	$938.0M
Basic earnings per share (in dollars per share)	$2.04	$0.39	$0.10	$0.52
Diluted earnings per share (in dollars per share)	$2.03	$0.39	$0.10	$0.52
Weighted-average basic shares outstanding (in shares)	1.8B	1.8B	1.8B	1.8B
Weighted-average diluted shares outstanding (in shares)	1.8B	1.8B	1.8B	1.8B

Balance sheet

AbbVie Inc. balance sheet, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Cash and equivalents	$5.2B	$5.5B	$12.8B	$9.2B
Short-term investments	$28.0M	$31.0M	$2.0M	$28.0M
Accounts receivable, net	$12.6B	$10.9B	$11.2B	$11.3B
Inventories	$5.0B	$4.2B	$4.1B	$3.6B
Prepaid expenses and other	$6.3B	$4.9B	$4.9B	$4.4B
Total current assets	$29.1B	$25.6B	$33.0B	$28.5B
Investments	$268.0M	$279.0M	$304.0M	$241.0M
Property and equipment, net	$5.6B	$5.1B	$5.0B	$4.9B
Intangible assets, net	$52.6B	$60.1B	$55.6B	$67.4B
Goodwill	$35.6B	$35.0B	$32.3B	$32.2B
Other assets	$10.7B	$9.1B	$8.5B	$5.6B
Total assets	$134.0B	$135.2B	$134.7B	$138.8B
Short-term borrowings	$2.5B	—	$0	$1.0M
Current portion of long-term debt and finance lease obligations	$6.1B	$6.8B	$7.2B	$4.1B
Accounts payable and accrued liabilities	$34.7B	$31.9B	$30.6B	$25.4B
Total current liabilities	$43.3B	$38.7B	$37.8B	$29.5B
Long-term debt and finance lease obligations	$58.9B	$60.3B	$52.2B	$59.1B
Deferred income taxes	$2.4B	$2.6B	$2.0B	$2.2B
Other long-term liabilities	$32.6B	$30.1B	$32.3B	$30.7B
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,838,678,628 shares issued as of December 31, 2025 and 1,831,594,494 as of December 31, 2024	18.0M	18.0M	18.0M	18.0M
Common stock held in treasury, at cost, 70,802,593 shares as of December 31, 2025 and 66,337,508 as of December 31, 2024	-9.1B	-8.2B	-6.5B	-4.6B
Additional paid-in capital	$22.5B	$21.3B	$20.2B	$19.2B
Accumulated deficit	($15.5B)	($7.9B)	($1.0B)	$4.8B
Accumulated other comprehensive loss	($1.1B)	($1.9B)	($2.3B)	($2.2B)
Total stockholders' equity (deficit)	($3.3B)	$3.3B	$10.4B	$17.3B
Noncontrolling interest	$42.0M	$39.0M	$37.0M	$33.0M
Total equity (deficit)	($3.2B)	$3.4B	$10.4B	$17.3B
Total liabilities and equity	$134.0B	$135.2B	$134.7B	$138.8B

AbbVie Inc. balance sheet, quarters

Line item	Jun 30, 2026	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025
Cash and equivalents	$6.6B	$9.4B	$5.6B	$6.5B
Accounts receivable, net	$13.8B	$12.5B	$12.8B	$12.6B
Inventories	$5.1B	$5.0B	$4.9B	$5.0B
Prepaid expenses and other	$8.1B	$6.6B	$5.2B	$5.2B
Total current assets	$33.7B	$33.5B	$28.5B	$29.3B
Investments	$266.0M	$268.0M	$291.0M	$310.0M
Property and equipment, net	$5.8B	$5.7B	$5.5B	$5.3B
Intangible assets, net	$49.1B	$50.9B	$54.3B	$57.0B
Goodwill	$35.5B	$35.6B	$35.6B	$35.6B
Other assets	$10.7B	$10.5B	$9.6B	$9.7B
Total assets	$135.1B	$136.5B	$133.9B	$137.2B
Short-term borrowings	$0	$0	$3.8B	$5.6B
Current portion of long-term debt	$8.3B	$8.3B	$2.0B	$2.0B
Accounts payable and accrued liabilities	$33.3B	$33.8B	$33.6B	$32.2B
Total current liabilities	$41.6B	$42.1B	$39.4B	$39.8B
Long-term debt	$62.5B	$64.5B	$63.0B	$63.0B
Deferred income taxes	$2.3B	$2.3B	$2.5B	$2.6B
Other long-term liabilities	$34.6B	$34.1B	$31.7B	$32.0B
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,844,174,521 shares issued as of June 30, 2026 and 1,838,678,628 as of December 31, 2025	18.0M	18.0M	18.0M	18.0M
Common stock held in treasury, at cost, 77,105,240 shares as of June 30, 2026 and 70,802,593 as of December 31, 2025	-10.6B	-10.6B	-9.1B	-9.1B
Additional paid-in capital	$23.2B	$23.0B	$22.3B	$22.0B
Accumulated deficit	($17.3B)	($17.9B)	($14.2B)	($11.5B)
Accumulated other comprehensive loss	($1.2B)	($1.2B)	($1.6B)	($1.5B)
Total stockholders' deficit	($5.9B)	($6.7B)	($2.6B)	($183.0M)
Noncontrolling interest	$47.0M	$44.0M	$43.0M	$45.0M
Total deficit	($5.9B)	($6.6B)	($2.6B)	($138.0M)
Total liabilities and equity (deficit)	$135.1B	$136.5B	$133.9B	$137.2B

Cash flow statement

AbbVie Inc. cash flow statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Net earnings	$4.2B	$4.3B	$4.9B	$11.8B
Depreciation	$762.0M	$764.0M	$752.0M	$778.0M
Amortization of intangible assets	$7.4B	$7.6B	$7.9B	$7.7B
Deferred income taxes	($492.0M)	($1.4B)	($2.9B)	($1.9B)
Change in fair value of contingent consideration liabilities	$6.5B	$3.8B	$5.1B	$2.8B
Payments of contingent consideration liabilities	($2.9B)	($2.0B)	($870.0M)	—
Stock-based compensation	$955.0M	$911.0M	$747.0M	$671.0M
Acquired IPR&D and milestones	$5.0B	$2.8B	$778.0M	$697.0M
Non-cash litigation reserve adjustments, net of cash payments	($933.0M)	$508.0M	($443.0M)	$2.2B
Impairment of intangible assets	$847.0M	$4.5B	$4.2B	$770.0M
Other, net	($3.0M)	($63.0M)	($225.0M)	($150.0M)
Accounts receivable	($1.5B)	$207.0M	$66.0M	($1.5B)
Inventories	($234.0M)	($319.0M)	($417.0M)	($686.0M)
Prepaid expenses and other assets	($827.0M)	$361.0M	($188.0M)	($264.0M)
Accounts payable and other liabilities	$951.0M	$177.0M	$3.8B	$1.6B
Income tax assets and liabilities, net	($762.0M)	($3.2B)	($488.0M)	$542.0M
Cash flows from operating activities	$19.0B	$18.8B	$22.8B	$24.9B
Acquisition of businesses, net of cash acquired	($204.0M)	($17.5B)	$0	($255.0M)
Other acquisitions and investments, net of cash acquired	($5.2B)	($3.0B)	($1.2B)	($539.0M)
Acquisitions of property and equipment	($1.2B)	($974.0M)	($777.0M)	($695.0M)
Purchases of investment securities	($35.0M)	($73.0M)	($77.0M)	($1.4B)
Sales and maturities of investment securities	$76.0M	$555.0M	$55.0M	$1.5B
Other, net	($29.0M)	$189.0M	$13.0M	$774.0M
Cash flows from investing activities	($6.6B)	($20.8B)	($2.0B)	($623.0M)
Net change in commercial paper borrowings with original maturities of three months or less	$499.0M	—	—	—
Proceeds from Short-Term Debt	$4.8B	$5.0B	—	—
Repayments of Other Short-Term Debt	($2.8B)	($5.0B)	—	—
Proceeds from issuance of long-term debt	$4.0B	$17.0B	—	$2.0B
Repayments of long-term debt and finance lease obligations	($6.8B)	($9.6B)	($4.1B)	($14.4B)
Debt issuance costs	($23.0M)	($99.0M)	($38.0M)	$0
Dividends paid	($11.7B)	($11.0B)	($10.5B)	($10.0B)
Purchases of treasury stock	($980.0M)	($1.7B)	($2.0B)	($1.5B)
Proceeds from the exercise of stock options	$172.0M	$214.0M	$180.0M	$262.0M
Payments of contingent consideration liabilities	$0	$0	($752.0M)	($1.1B)
Other, net	$68.0M	$57.0M	$48.0M	$30.0M
Cash flows from financing activities	($12.7B)	($5.2B)	($17.2B)	($24.8B)
Effect of exchange rate changes on cash and equivalents	$42.0M	($65.0M)	$5.0M	($62.0M)
Net change in cash and equivalents	($295.0M)	($7.3B)	$3.6B	($545.0M)
Cash and equivalents, beginning of year	$5.5B	$12.8B	$9.2B	$9.7B
Cash and equivalents, end of year	$5.2B	$5.5B	$12.8B	$9.2B
Interest paid, net of portion capitalized	$3.0B	$2.8B	$2.5B	$2.5B

AbbVie Inc. cash flow statement, quarters

Line item	Jun 30, 2026 · YTD	Mar 31, 2026 · Q1	Sep 30, 2025 · YTD	Jun 30, 2025 · YTD
Net earnings	$4.3B	$697.0M	$2.4B	$2.2B
Depreciation	$382.0M	$188.0M	$559.0M	$367.0M
Amortization of intangible assets	$3.4B	$1.7B	$5.6B	$3.7B
Deferred income taxes	($58.0M)	$137.0M	($107.0M)	($300.0M)
Change in fair value of contingent consideration liabilities	$3.9B	$2.4B	$5.1B	$4.3B
Payments of contingent consideration liabilities	($1.8B)	($722.0M)	($2.2B)	($1.4B)
Stock-based compensation	$610.0M	$444.0M	$798.0M	$589.0M
Acquired IPR&D and milestones	$1.0B	$744.0M	$3.8B	$1.1B
Non-cash litigation reserve adjustments, net of cash payments	$86.0M	$150.0M	($1.1B)	($750.0M)
Other, net	($18.0M)	($22.0M)	$6.0M	$96.0M
Accounts receivable	($1.3B)	$87.0M	($1.7B)	($1.5B)
Inventories	($327.0M)	($184.0M)	($209.0M)	($211.0M)
Prepaid expenses and other assets	($338.0M)	($150.0M)	($169.0M)	($257.0M)
Accounts payable and other liabilities	($392.0M)	($1.6B)	$1.5B	($181.0M)
Income tax assets and liabilities, net	($2.3B)	($81.0M)	($1.4B)	($997.0M)
Cash flows from operating activities	$7.3B	$3.8B	$13.8B	$6.8B
Acquisitions of businesses, net of cash acquired	$0	$0	($204.0M)	($204.0M)
Other acquisitions and investments, net of cash acquired	($1.1B)	($266.0M)	($4.1B)	($1.3B)
Acquisitions of property and equipment	($587.0M)	($265.0M)	($885.0M)	($504.0M)
Other, net	($94.0M)	($43.0M)	($28.0M)	$49.0M
Cash flows from investing activities	($1.8B)	($574.0M)	($5.2B)	($1.9B)
Net change in commercial paper borrowings with original maturities of three months or less	($499.0M)	($499.0M)	$999.0M	$1.5B
Proceeds from issuance of other short-term borrowings	$0	—	$4.8B	$4.0B
Repayments of other short-term borrowings	($2.0B)	($2.0B)	($2.0B)	$0
Proceeds from issuance of long-term debt	$8.0B	$8.0B	$4.0B	$4.0B
Repayments of long-term debt	($2.0B)	$0	($6.8B)	($6.8B)
Dividends paid	($6.2B)	($3.1B)	($8.7B)	($5.8B)
Purchases of treasury stock	($1.5B)	($1.5B)	($977.0M)	($973.0M)
Other, net	$27.0M	$2.0M	$69.0M	$32.0M
Cash flows from financing activities	($4.1B)	$919.0M	($8.6B)	($4.0B)
Effect of exchange rate changes on cash and equivalents	($19.0M)	($12.0M)	$31.0M	$39.0M
Net change in cash and equivalents	$1.3B	$4.2B	$105.0M	$943.0M
Cash and equivalents, beginning of period	$5.2B	$5.2B	$5.5B	$5.5B
Cash and equivalents, end of period	$6.6B	$9.4B	$5.6B	$6.5B

AbbVie Inc. score and earnings-call analysis · All covered companies

Figures as reported in SEC filings. General information, not investment advice.